



Powered by  AdvaMed

MedTech Innovator Showcase 2017 Company Lookbook

MedTech Innovator

The industry's nonprofit global competition and accelerator for medical device, digital health, and diagnostic companies.

Our mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system.



Table of Contents

Sponsors.....	4
MedTech Innovator Showcase Schedule.....	5
2Morrow.....	7
Abreos Biosciences.....	8
Access Vascular.....	9
Advanced Prenatal Therapeutics	10
Alleviant Medical.....	11
Allotrope Medical.....	12
Aqueduct Critical Care.....	13
Arterys.....	14
Avenda Health.....	15
Centerline Biomedical.....	16
Day Zero Diagnostics.....	17
EBS Technologies.....	18
Encellin.....	19
Evoke Medical.....	20
Eximis Surgical.....	21
ExplORer Surgical.....	22
Genetesis.....	23
Genomic Expression.....	24
GreenLight Medical.....	25
Harbor MedTech.....	26
HemaFlo Therapeutics.....	27
Innoblative Designs.....	28
Landsdowne Laboratories.....	29
M&S Biotics.....	30

MetaOptima.....	31
mOm Incubators.....	32
Myonic.....	33
MYOVUE.....	34
Nanowear.....	35
Nexeon MedSystems.....	36
NovaGray.....	37
OncoTab, Inc.....	38
Osso VR.....	39
Otricath.....	40
palmm.....	41
Patientory.....	42
PeriCor.....	43
PharmaJet.....	44
Pneumonics, Inc.....	45
Promaxo.....	46
Redox.....	47
Revolutionary Medical Devices.....	48
RxAssurance.....	49
Selio Medical.....	50
Trayt Health.....	51
VADovations.....	52
VerteCore Technologies.....	53
Voyager Biomedical.....	54
Zebra Medical Technologies.....	55

Welcome to



Thank you for joining us for the MedTech Innovator Showcase, a series of 11 interactive sessions each featuring four or five companies under a common technology theme.

MedTech Innovator Thanks Our Sponsors & Scholarship Supporters!

MedTech Innovator was Founded with Support from



Additional Support is Provided by



The Showcase is Brought to You by

Platinum
Sponsor



Gold
Sponsor



Showcase Scholarships are Supported by



MedTech Innovator Showcase Schedule

Tuesday, September 26

In Vitro Diagnostics 9:10 - 9:50 AM <i>Moderator: Jennifer Paine, Executive Vice President, Worldwide Quality, Regulatory & Compliance, Ortho Clinical Diagnostics</i>		Health Care IT & Digital Health 9:55 - 10:35 AM <i>Moderator: Tina Moen, PharmD, Deputy Chief Health Officer, IBM Watson Health</i>		Orthopedic 10:45 - 11:35 AM <i>Moderator: Todd Harrington, Vice President, Strategic Development & Professional Affairs, Stryker</i>		Wound Healing & Dermatology 11:40 - 12:20 PM <i>Moderator: Rob Albert, Senior VP & Chief Marketing Officer, B. Braun Medical</i>		Therapeutic Delivery & Dosing 2:10 - 2:50 PM <i>Moderator: Jordan Tuttle, Vice President, Strategic Investments, BTG</i>		Vascular & Neurovascular 2:55 - 3:45 PM <i>Moderator: George Serafin, National Managing Principal, Healthcare & Life Sciences, Grant Thornton</i>	
Page #											
Day Zero Diagnostics	17	2Morrow	7	Evoke Medical	20	Harbor MedTech	26	Abreos Biosciences	8	HemaFlo Therapeutics	27
Genomic Expression	24	GreenLight Medical	25	MYOVUE	34	Landsdowne Labs	29	Encellin	19	Myonic	33
NovaGray	37	Redox	47	Osso VR	39	MetaOptima	31	Otricath	40	Nexeon MedSystems	36
OncoTab	38	RxAssurance	49	VerteCore Technologies	53	Zebra Medical Technologies	55	PharmaJet	44	PeriCor	43
										Voyager Biomedical	54

MedTech Innovator Showcase Schedule

Wednesday, September 27

Pulmonology & Critical Care 8:10 - 9:00 AM <i>Moderator: Gabriele Brambilla, Chief Executive Officer, Alira Health</i>		Consumer Health 9:05 - 9:45 AM <i>Moderator: Colin Lawlor, Chief Executive Officer, SleepScore Labs</i>		Surgical Tools & Planning 9:50 - 10:40 AM <i>Moderator: Amy Len Kobe, Director, Baxter Ventures</i>		Advanced Imaging Diagnostics 10:45 - 11:35 PM <i>Moderator: K.C. Hasson, Ph.D., Senior Manager, Business Development & Innovation, Canon BioMedical</i>		Cardiovascular 11:40 - 12:30 PM <i>Moderator: Julia Stubben, MBA, VP European Sales & Marketing, CVRx</i>	
Page #									
Aqueduct Critical Care	13	EBS Technologies	18	Allotrope Medical	12	Arterys	14	Access Vascular	9
mOm Incubators	32	palmm	41	Eximis Surgical	21	Avenda Health	15	Advanced Prenatal Therapeutics	10
Pneumonics	45	Patientory	42	ExplORer Surgical	22	Centerline Biomedical	16	Alleviant Medical	11
Revolutionary Medical Devices	48	Trayt Health	51	Innoblative Designs	28	Genetesis	23	Nanowear	35
Selio Medical	50			M&S Biotics	30	Promaxo	46	VADovations	52



Kirkland, WA

Clinically-tested, mobile behavior change platform for improving health & wellness



Brandon Masterson
Founder & CEO
bmasterson@2morrowinc.com



Jo Masterson, RN
Co-Founder & COO



Kim Hansen
CTO



Evan Forman, PhD
CSO

- 2Morrow integrates behavioral science, clinical trials, & user experience to deliver effective behavior change programs that actually work
- Based on Acceptance & Commitment Therapy (ACT), the core program was developed/tested over 6 yrs. w/ \$10M in NIH funded R&D at Fred Hutch Cancer Research Center
- 2Morrow Health – one proprietary platform, multiple programs for weight, stress, smoking & chronic pain
- Flagship product, SmartQuit, is the first smoking cessation app proven effective in clinical trials
- Two published clinical trials show SmartQuit increases a smoker’s chance of quitting 2-3x
- Large employer realized 5x more participants & 5x more quitters than their tele-coaching program w/ 50% of survey respondents reporting they are smoke-free

Significant Milestones

Two published clinical trials on app. 6 RCT on ACT for smoking cessation. ACT found to be 2X more effective for cessation

Launched “2Morrow Health” (2017)

Worldwide license, US Patent PCT Filed

Clients: WA DOH, Wellness Platforms, Employers, Health Plans, Nonprofits

Raised \$980K (angels, grants, & founders)

Fundraising

Seeking \$3M Seed



Presenting in the **Tuesday**
Health Care IT & **September 26**
Digital Health Showcase **9:55 am - 10:35 am**





Bradley Messmer, PhD
Founder & CEO
bmessmer@abreosbio.com



Michael Little, PhD
VP BD



Laura Ruff, PhD
Director, R&D



William Yashar
Director, BD



Jessica Pfeilsticker, PhD
Director, Assay Development

Presenting in the
Therapeutic Delivery &
Dosing Showcase

Tuesday
September 26
2:10 pm - 2:50 pm

Precision dosing of biologic drugs to maximize clinical outcomes & minimize side effects

- The Veritope™ platform is a proprietary reagent platform that enables clinicians to deliver personalized, precision dosing tailored to the individual needs of patients
- Veritopes™ measure levels of a given biologic or biosimilar drug in the blood & can be implemented in any immunoassay format for laboratory or point of care testing
- Extensive Veritope™ pipeline consisting of 19 Veritopes™ against marketed biologic drugs
- Veritope™ dose monitoring tests are unique personalized medicine tools that enhance biologic drugs by differentiating products in crowded markets, stratifying patients in clinical trials, & improving access to value-based reimbursement

Significant Milestones

US patent awarded protecting key IP

Custom services deals with pharma for biosimilar & antibody-drug conjugate targets

Advanced discussions with pharma for custom services & complementary diagnostics deals

Raised \$2.3M to-date in equity funding

Fundraising

Seeking \$8M Series A



Laboratory



Near Patient



Point of Care



James Biggins
Founder, President & CEO
jbiggins@accessvascularinc.com



Michael Bassett
VP R&D

Novel bulk-hydrophilic biomaterial that reduces thrombotic risk & complications

- Access Vascular is developing a platform of venous access devices using novel bulk-hydrophilic biomaterial technology that prevents blood component accumulation (thrombus)
- Proprietary biomaterial is not recognized by the body as foreign material & therefore does not trigger the body's thrombotic response, starting a cascade of events that leads to catheter occlusion & bacterial colonization. Net result is improved procedural efficiencies, higher quality of care, & improved reimbursement
- Flagship device is the HydroPICC™, a peripherally inserted central catheter
- In testing, HydroPICC™ showed up to 98% reduction in thrombus accumulation demonstrating the potential for superior clinical outcomes with lower associated healthcare costs when compared to existing technologies
- Robust pipeline includes midlines, dialysis catheters & ports

Significant Milestones

Provisional patent filed

Fully-functional prototype built

FDA 510(k) pathway confirmed for HydroPICC™

Manufacturing facility build out in progress

Funding

Access Vascular has secured private financing, with sufficient funding to support FDA submission for HydroPICC™ & expansion of manufacturing capabilities





James Smith, PhD
CEO & President



Henry Smith, PhD
Chairman of the Board



Dan Thiel
VP Business Development
dthiel@advancedprenatal.com

Medical device specifically designed to treat preeclampsia

- Specific treatment for preeclampsia, utilizing a proprietary Targeted Apheresis Column for Preeclampsia (TAC-PE)
- Patented technology selectively targets the removal of blood components associated with the symptoms of preeclampsia, preserving natural & vital blood components
- Aims to relieve symptoms of preeclampsia, such as high blood pressure, so pregnancy can be safely prolonged
- Extending pregnancy duration reduces the risk of lifelong disabilities associated with prematurity, decreases healthcare costs, & helps mothers & babies survive
- Easy integration into existing therapeutic apheresis devices
- Enables a fundamental shift in how patient care is delivered – from critical care & NICU to preventive care in the maternity ward

Significant Milestones

US patent granted


Proprietary binding agent for sFlt-1 developed

Commercial prototype under development

Collaborating with University of New Mexico for clinical observational study

Fundraising

Seeking \$5M Series A



Houston, TX



Jacob Kriegel, MD
Co-Founder & CEO
jacob.kriegel
@alleviantmedical.com



Avni Patel
Co-Founder & COO



Alex Arevalos, PhD
Co-Founder & CTO



Albertien Greijdanus
Co-Founder & CCO

Presenting in the
Cardiovascular
Showcase

Wednesday
September 27
11:40 am - 12:30 pm

Minimally invasive device to treat heart failure through reduction of elevated left atrial pressure


- Transcatheter device that relieves pressure buildup within the left atrium, which is the key driver of heart failure symptoms & hospitalizations
- Single use disposable device
- Simple, low-risk cath lab procedure
- Target population: Patients w/ mild, moderate, & severe heart failure
- \$5B total addressable market (based on \$500K eligible patients annually in US & EU)
- Designed to relieve patient symptoms, improve quality of life, & reduce hospital readmissions due to heart failure exacerbations

Significant Milestones


Provisional patents filed (conversion Q1 2018)
Multiple working prototypes built & successfully tested in swine models
Preclinical pilot study initiated Q3 2017 at Houston Methodist Hospital

Fundraising

Seeking \$1.5M Seed



LEFT ATRIAL PRESSURE BUILDUP
PRE-TREATMENT



SHUNT OFFLOADS TO RIGHT ATRIUM
POST-TREATMENT

Houston, TX



Albert Huang, MD
Founder & CEO
albert@allotropemed.com



Jeff Castleberry, PE, MBA
COO



Don Gonzales, MD
Board of Directors



Mira Sahney, MS, MBA
Board of Directors



David Franklin, MBA
Board of Directors

Presenting in the
Surgical Tools &
Planning Showcase

Wednesday
September 27
9:50 am - 10:40 am

Innovative surgical solutions that improve patient outcomes by reducing procedure time & injury risk

- Flagship device is StimSite: A handheld, single use, battery powered device that quickly, easily & safely allows the surgeon to identify the ureter during minimally invasive surgery
- StimSite is applicable in over 3M cases in the US & may eliminate additional procedures, increase OR throughput, decrease injury risk & decrease non-reimbursed surgical costs
- No pre-submission clinicals projected to be required, & 510(k) clearance for StimSite anticipated Q4 2018 with early market entry Q1 2019
- Platform technology with applications in esophageal, gastric, small intestine & colonic disease states & surgical procedures
- Technology is easily integrated into existing electrosurgical devices & systems

Significant Milestones

8 patents filed in US, EU, & China protecting system & methods for ureter detection & smooth muscle stimulation via electrical stimulation (with expanded clinical & technologic applications)

Large animal studies performed showing efficacy in thickened/scarred as well as normal tissues

Selected as top innovation by panel of surgeons during the 2017 SAGES conference (one of the largest minimally invasive surgical organizations in the world)

Fundraising

Seeking \$3M Series A



Bothell, WA



Thomas Clement
President & CEO
tclement@aqueduct.cc



Samuel Browd, MD, PhD
Co-Founder & CMO



Barry Lutz, PhD
Co-Founder & CTO

Transforming the way patients with temporary external CSF drains are managed

- The Smart External Drain is an external self-adjusting CSF drainage system designed to eliminate continuous manual adjustments & interventions by trained nursing staff
- Patient specific settings & alarm parameters
- Reduces number of adjustments required of critical care nurses
- Potential to transfer otherwise healthy patients from expensive critical care to step-down care
- Patient complications & co-morbidities associated with incorrect adjustments or inadvertent patient movements may be reduced enhancing patient safety

Significant Milestones

1 patent granted, 16 patents filed
510(k) clearance obtained in Q4 2016
Special 510(k) Q2 2017 software upgrade
Marketing study with 10 patients Q3 2017

Fundraising

Seeking \$6M Series B



Presenting in the
Pulmonology &
Critical Care Showcase

Tuesday
September 27
8:10 am - 9:00 am



San Francisco, CA

Intelligent cloud supercomputing platform for medical imaging analysis



Fabien Beckers, PhD
Co-Founder & CEO
fabien@arterys.com



John Axerio-Cilies, PhD
Co-Founder & COO



Albert Hsiao, MD, PhD
Medical Co-Founder



Shrevas Vasanawala, MD, PhD
Medical Co-Founder

- Advanced software platform for medical image interpretation, combining cloud supercomputing & AI to provide doctors with the information they need to make confident care decisions
- Apps enable physicians with speed, accuracy, & the power of data-driven diagnoses
- First AI product contours cardiac anatomy as accurately as experts, but in 15-20 secs. instead of the 45-60 mins. required to do it manually
- 4D Flow scan is far more comprehensive vs. traditional methods, & is ~\$200 less expensive
- Significant market traction with 10K+ patients scanned at 45+ active sites
- Future plans include expanding product offerings to assist radiologists in the detection, identification, measurement & tracking of lesions associated with different cancers

Significant Milestones

Received first ever FDA clearance, CE mark & Health Canada clearance for a Cloud/AI product
Cloud/AI platform FDA cleared Q1 2017
Established partnerships w/ Siemens & GE

Fundraising

Seeking \$25M Series B



Presenting in the **Wednesday**
Advanced Imaging **September 27**
Diagnostics Showcase **10:45 am - 11:35 am**



Los Angeles, CA



Leonard Marks, MD
Chief Medical Officer



Shyam Natarajan, PhD
President
shyam@avendahealth.com



Brittany Berry-Pusey, PhD
VP BD & Strategy

Presenting in the **Wednesday**
Advanced Imaging **September 27**
Diagnostics Showcase **10:45 am - 11:35 am**

Image-guided laser ablation to treat prostate cancer in a doctor's office

- Focal laser ablation, proprietary sensor enabling in-office treatment
- Integrated treatment planning using machine learning
- Outpatient procedure
- Backed by peer-reviewed science
- Market opportunity: 60-80K men/year in the US; \$4B

Significant Milestones

Feasibility study (10 patients) at UCLA completed in Q3 2016

All patients:

Minimal anesthesia required

Successful ablation demonstrated

No incontinence or loss of sexual function

Fundraising

Seeking \$2M Seed



Targeted Tumor Ablation
“The Male Lumpectomy”



Jai Gupta, PhD
Chairman & CEO



Vinod Goel, PhD
President & Director



Vikash Goel
Inventor & CTO
v@centerlinebiomedical.com



Uday Gupta
Director, BD

3D visualization & navigation, predictive analytics & training for minimally-invasive procedures


- IOPS™ (Intra-Operative Positioning System) delivers three-dimensional visualization & real-time navigation minimizing exposure to high-dosage radiation & toxic contrast dyes
Benefit: Increase patient & surgeon safety
- IOPS' mathematical anatomical modeling capabilities would provide predictive vessel motion & deformation renderings enabling surgeons & practitioners to better prepare for & react during each case, improving patient outcomes
Benefit: Reduce costs per case while improving OR utilization rates
- Will address multiple markets, including peripheral artery disease, bronchoscopy, carotid aneurysm, cerebral aneurysm, electrophysiology, endovascular aortic repair, & coronary intervention & stenting
Benefit: A platform technology to address 4+ million cases annually

Significant Milestones

Raised \$11.7M to date (Cleveland Clinic, G2 Venture Group, & private investors)

Fundraising

Seeking \$12-17M Series B



Navigating a catheter (arrow) using fluoroscopy (left) versus IOPS (right). Actual clinical images from same patient at same moment in time.



Boston, MA

Whole genome sequencing & machine learning to rapidly diagnose & treat serious infections

- DZD is developing a new class of diagnostic that enables physicians to start targeted antibiotics within hours rather than days
- DZD works directly from clinical samples, obviating the need for culture, & utilizes the whole genome sequencing data as input into a machine learning algorithm to predict antibiotic resistance quickly & comprehensively
- Faster diagnosis & resistance profiling leads to faster, more effective treatment which can significantly decrease mortality & cost.
- DZD enables reduced use of broad spectrum antibiotics, which can be expensive, exposes patients to significant toxicity, encourages further resistance & has become increasingly ineffective.
- Machine learning algorithm learns from a large training database initially built w/ 30,000 samples from Mass General Hospital
- Initially targeting application in sepsis diagnosis & treatment

Significant Milestones

Developed proof of concept prototype for each component of integrated system

Signed exclusive license for commercial use of database used in algorithm development

Funding

Raised \$3.5M Seed



Jong Lee, MBA
President & CEO
jong@dayzerodiagnosics.com



Doug Kwon, MD, PhD
Clinical Lead



Melis Anahtar, MD, PhD
Biomedical Lead



Miriam Huntley, PhD
Genomics Lead



Dougal Maclaurin, PhD
Software Lead

Presenting in the
In Vitro Diagnostics
Showcase

Tuesday
September 26
9:10 am - 9:50 am





Brandenburg, Germany



Karl Schweitzer
CEO
karl.schweitzer@ebstech.de

Presenting in the
Consumer Health
Showcase

Wednesday
September 27
9:05 am - 9:45 am



Non-invasive optic nerve stimulation device for restoring vision

- EYETRONIC is a non-invasive ONS therapy for the treatment of visual field defects caused by disorders of the optic nerve, such as glaucoma, eye infarct, trauma or stroke
- Consists of stimulation goggles, EEG cap, patient unit & supervisor unit
- Therapy carried out in the doctor's office in 10 sessions of 60-90 minutes held on 10 consecutive working days
- Patient adaptable for individualized therapy
- 300 patients have been treated with 95%+ satisfaction rate & no observed SAEs

Significant Milestones

Received CE mark

Secured portfolio of 7 patent families

Completed Class Ib (RCT) trials showing efficacy & safety

Fundraising

Seeking €10M Series D





San Francisco, CA



Crystal Nyitray, PhD
Founder, Inventor, & CEO
crystal@encellin.com



Grace Wei, PhD
Founder & COO



Ronald Martell
Executive Chairman



Tejal Desai, PhD
Advisor & Inventor



Vern Norviel
IP, Council at WSGR

Presenting in the
Therapeutic Delivery &
Dosing Showcase

Tuesday
September 26
2:10 pm - 2:50 pm



Implantable ultra thin-film cell delivery technology for diabetes management

- Implantable cell delivery technology that protects insulin-secreting cells from the immune system
- Provides access to cell therapy solutions for Type 1 diabetics without immunosuppression
- Demonstrated proof of concept:
 - Detects glucose & secretes insulin appropriately
 - Neovascularization without fibrosis *in vivo*
 - Immunoprotection in an allotransplant model *in vivo*
- Provides a long-term auto-regulation therapeutic solution for Type 1 diabetes

Significant Milestones

Utility patent filed Q1 2016

Pre-IND meeting with FDA Q1 2018


First in man study initiated Q3 2018 to demonstrate safety & immunoprotection

Enable device manufacturing validation

To date: \$6.6M through grants from sources including NSF, JDRF, Sandler Foundation, Roger Foundation, & Whitaker Foundation

Fundraising

Seeking \$4M Series A





Lawrence, KS

Biomechanically powered, osteoinductive spinal fusion implant



Leighton LaPierre
Co-Founder & CEO
leighton@evokemedical.co



Lisa Friis, PhD
Co-Founder & CTO



Paul Arnold, MD
Co-Founder & CMO


- Spinal interbody fusion implant with built in electrical stimulation properties to improve bone healing
 - Reduces reoperation due to failed fusion
 - Quicker, more robust fusion
 - Addresses difficult to fuse population
- Implant mimics natural healing properties of bone (i.e. Wolff's Law)
- Passively powered device, which does not require a battery
- Eliminates the need for expensive & unproven adjunct therapies such as BMP, other biologics, or external electrical stimulators
- Fusion Diagnostic Capabilities – device can externally indicate fusion progress (secondary revenue stream)
- Other bone healing applications outside of spine

Significant Milestones

Patents pending for platform material technology
Prototype & proof of concept animal study completed – advanced bone healing demonstrated
Awarded \$225K NIH STTR Phase I Grant

Fundraising

Seeking \$750K Seed



Presenting in the
Orthopedic
Showcase

Tuesday
September 26
10:45 am - 11:35 am





Chicago, IL



Jennifer Fried
CEO
jennifer@explorersurgical.com



Alex Langerman, MD
CMO



Tom Knight
COO



Eugene Fine
CTO

Presenting in the
Surgical Tools &
Planning Showcase

Wednesday
September 27
9:50 am - 10:40 am



Digital surgical playbook to improve intraoperative communication & efficiency

- An interactive platform that builds on each team member's procedural knowledge to improve intraoperative communication, awareness, & patient safety
- Provides surgical team members with a digital, role-specific reference in real-time, complete with pictures & videos of materials, room setups, patient positioning, & technical steps of the case
- Analytics component may be used to improve hospital efficiency by tracking OR team performance & optimizing resource management
- Demonstrated to reduce intraoperative disruptions arising from missing or incorrect instruments, reduce set-up time, & reduce wasted disposables

Significant Milestones

5 staged implementations at large academic & community medical centers around the US; several medical device & durable medical equipment partners & customers

Funding

Closed \$3.3M Series A Q3 2017, led by Aphelion Capital





Louisville, CO

Device for the safe, fast removal of large specimens during minimally invasive surgeries



Kristin Johnson
Co-Founder & CEO
kristin.johnson
@eximissurgical.com



Donna Ford-Serbu
Co-Founder



Bill Gregg
Co-Founder



Dirk Johnson
Co-Founder


- XCor allows surgeons to quickly & easily remove large specimens through small incisions while creating clean cut segments more adequate for pathology
- Solves current problems associated w/ morcellators including preventing the spread of unknown cancers in a patient's abdomen
- Reduces procedure time from ~45 mins. to 5 mins. saving valuable physician & operating room time
- Patients benefit from shorter anesthesia times & smaller incisions that reduce pain, recovery time, & post-operative complications
- Potential to expand into other gynecologic, general, hepatobiliary, pediatric, & thoracic surgeries

Significant Milestones

Completed proof of concept w/ positive feedback from 26 surgeons, all of whom will adopt XCor once FDA approved

Fundraising

Seeking \$4.5M Series A



Presenting in the
Surgical Tools &
Planning Showcase

Wednesday
September 27
9:50 am - 10:40 am





Cincinnati, OH



Peeyush Shrivastava
CEO
peeyush@genetesis.com



Chandan Srivastava
CFO



Alisa Nicksch, MD
CMO

Presenting in the **Wednesday**
Advanced Imaging **September 27**
Diagnostics Showcase **10:45 am - 11:35 am**



Passive imaging of the heart's electric currents for applications in the ER

- CardioFlux passively, & w/out patient contact, measures the cardiac-generated magnetic fields emanating from a patient's chest
- Portable technology that can be wheeled to the bedside of the emergency room
- Sensitivity & specificity of the system to ischemia in patients w/ unstable angina is comparable to stress imaging, yet can be performed in seconds & w/out patient risk
- CardioFlux analytical tools showed a 79% improvement over ECG, 40% improvement over troponin in detecting ischemia, & demonstrated competitiveness w/ stress echocardiography


Significant Milestones

Completed 30 patient retrospective study at the Mayo Clinic

NVIDIA Social Impact Award Winner (\$375K)

Fundraising

Seeking \$7M Series A





Boston, MA



Gitte Pedersen
Founder & CEO
glp@genomicexpression.com



Morten Pedersen
CTO



Jesper Zeuthen
CMO



Morten Middelfart
CIO



Tany Kanigan
COO

Presenting in the
In Vitro Diagnostics
Showcase

Tuesday
September 26
9:10 am - 9:50 am



RNA-sequencing based technology for identifying the appropriate therapy for cancer patients

- Diagnostic service linking sequencing to known therapies & clinical trial options, maximizing outcomes
- Genetic driver identification allows earlier diagnosis & truly individualized treatment planning based on scientific outcomes across the treatment spectrum
- Cloud-based solution generating a personalized, actionable report for each tumor based on its gene expression profile
- Minimizes side effects from inappropriate, standardized treatment regimens & generalized dosing

Significant Milestones

Established partnership with OvaCure.org
Diagnostic partner for the \$32M Genome Denmark project
Top 10 in XTC 2015

Fundraising

Seeking \$10M Series A





Nashville, TN



Austin Dirks
Founder & CEO
austin@greenlightmedical.com



Troy Kyle
COO & Director



Stephen Saine
CTO

Cloud-based software to streamline hospital value analysis of new medical technology


- All-in-one software to connect medical suppliers with hospitals for the introduction, review, & approval of new medical technology within hospital value analysis
- Provides workflow solution, project management, & data repository for hospitals
- Provides standardization of new product request process, transparency to sales cycle, & access to key stakeholders for medical device suppliers
- Cloud-based automation has enabled a 35-day average from submission to decision
- Deployed in 24 hospitals, 1 ambulatory surgery center, with 1000+ hospital users & 600+ medical device sales reps representing 300+ medical device companies
- Signing deal w/ large IDN to add >100 hospitals to portal
- Announcing release of Corporate portal for medical device manufacturers

Significant Milestones

Backed by Jumpstart Foundry, TMCx, & Healthbox
Featured in Forbes & Google Demo Day
RESI Innovation Challenge 2nd place winner
Raised \$1.2M to date from family, friends, physicians, & angel investors

Fundraising

Seeking \$3-4M Series A



Presenting in the **Tuesday**
Health Care IT & **September 26**
Digital Health Showcase **9:55 am - 10:35 am**





Jerry Mezger
President & CEO
jerrym@harbormedtech.com



Keith Myers
CTO



Jim Klinger
CFO



Jon Zalk
CCO

Next generation skin substitute for use in managing complex skin wounds


- Independent study by the Ohio State University Regenerative Medicine Center discovered that our patented BriDGE® technology actively recruits the patient's own growth factors to dramatically accelerate healing while preventing infections & inhibiting scar formation
- Two products FDA approved & CE Marked, with five products in near-term pipeline targeting orthobiologics, general & plastic surgery
- Clinical studies of first product, Architect®, show that it heals complex wounds twice as fast as competitive products with just one application, improving patient outcomes at a much lower cost to the healthcare system
- Next product, EPMatrix™, will be first biologic surgical mesh to bioactively accelerate healing & prevent infections in surgical repairs of torn ligaments & tendons

Significant Milestones

Received FDA approval & CE Mark on Architect Stabilized Collagen Matrix

Fundraising

Seeking up to \$15M Series C





Carlsbad, CA



Michael Martino
President & CEO



Dale Peterson, PhD
CSO
dpeterson@hemaflo.com

Treating AKI with a Drag-reducing polymer that doubles blood flow without increasing blood pressure

- Acute kidney injury (AKI) is an unintended consequence of hospitalization that impacts 7.0 million ICU patients a year in the US, resulting in 3.2 million severe cases & 790,000 deaths, & adds \$34,000 in incremental costs to treat each severe case.
- NephroFlow[®] is formulated with drag-reducing polymer (DRP) to dramatically increase blood flow in patients without increasing the strain on their heart
- Single administration produced a statistically significant improvement in kidney function within 24 hours in animal studies & cut their death rate in half.
- Product is stable at room temperature, easy to administer through IV bag, & composed solely of FDA approved excipients.

Significant Milestones

- Secured FDA designation as a device
- Pilot animal studies completed
- Patents issued covering core technology
- Raised \$380K to date

Fundraising

Seeking \$8M Series A to complete First-in-Human clinical study



Presenting in the **Tuesday**
Vascular & **September 26**
Neurovascular Showcase **2:55 pm - 3:45 pm**



Chicago, IL



Tyler Wanke
Co-Founder & CEO
tyler@innoblative.com



Bob Rioux
CTO & COO



Roberta Lee, MD
CMO



Anna Lisa Somera
VP Reg. Quality & Clinical



Victor Simoes
VP Finance & Strategy

Presenting in the
Surgical Tools &
Planning Showcase

Wednesday
September 27
9:50 am - 10:40 am

Intelligent, deep-learning device for personalized ablative cancer treatment

- SIRA is a saline-assisted intra-cavitary radiofrequency ablation device for the treatment of breast cancer & other soft-tissue diseases
- SIRA-S technology automatically senses real-time ablation status using deep-learning (artificial intelligence) in three-dimensions & creates accurate custom treatment geometries
- Innoblative's devices destroy residual cancer in minutes & in one treatment
- The treatment aims to reduce reoperations, eliminate the need for radiation therapy in early stage patients, & decrease the direct & indirect costs of cancer treatment
- Proof-of-concept clinical trial complete at UAMS & subsequent studies underway at Northwestern University & expanding to multiple centers

Significant Milestones

Design freeze completed
Usability study completed
Proof of concept clinical study completed
FDA pre-submission meeting completed
Winner of M2D2 \$100K Challenge 2016
Raised \$5M+ to date from angel investors

Fundraising

Seeking Series A



Landsdowne Laboratories

Englewood, NJ



Melissa Fensterstock
Co-Founder & CEO
melissa@landsdownelabs.com



Theresa Tribble
Co-Founder



Robert Langer, ScD
Co-Founder



Jeff Karp, PhD
Co-Founder

Presenting in the
Dermatology & Wound
Healing Showcase

Tuesday
September 26
11:40 am - 12:20 pm



Quick release medical tape designed for use on patients with fragile skin

- Uses standard adhesives configured in novel ways to provide a medical tape that offers secure adhesion while being quickly & easily removable
- Adhesive product minimizes skin tearing for patients with fragile skin such as premature infants & elderly
- Improves wound management & reduces infection risk


Significant Milestones

Exclusive option in place to license technology from Brigham & Women's Hospital

Children's National Hospital Pediatric Device Innovation Competition Winner (\$25K)

Fundraising

Seeking \$1.1M Seed





Houston, TX



Joshua Mecca
Co-Founder & President
joshua.mecca@msbiotics.com



John Strauss
Co-Founder & VP



Thomas Gallagher
Director, Financial Ops

Presenting in the
Surgical Tools &
Planning Showcase

Wednesday
September 27
9:50 am - 10:40 am



Combining RFID technology & AI to create more efficient, effective, & safer surgical procedures

- Currently, 14% of operative time is spent counting surgical sponges, with 1 in 8 surgical procedures having a counting discrepancy due to this manual process; worse yet, less than 20% of surgical instruments are utilized during the course of the procedures
- Combined, this costs hospitals millions of dollars in costs & lost productivity
- M&S Biotics addresses this problem with the Biotic Integration System, which automates the surgical counting process while providing downstream analytics to supply chain to create more uniform & standard surgical sets
- Biotic (RFID) system is the first autonomous system with the ability to detect, track, count, & locate surgical items in real-time
- Biotic Insight platform provides data analytics regarding instrument utilization

Significant Milestones

Partnerships with Stony Brook University School of Medicine & Baylor College of Medicine, Startup Health, & TMCx

Signed LOI's with two hospital systems

Signed pilot agreements with Highland Surgical Center & Southampton Hospital

Pending sale with Seton Medical Center at University of Texas (Austin)

Fundraising

Seeking \$1M Seed





Vancouver, Canada



Maryam Sadeghi, PhD
Co-Founder & CEO
maryam@metaoptima.com



Majid Razmara, PhD
Co-Founder & CTO



Sean Hodgins
CFO

Presenting in the
Dermatology & Wound
Healing Showcase

Tuesday
September 26
11:40 am - 12:20 pm



DermEngine: intelligent data-driven clinical platform for diagnostics & therapeutics in dermatology

- More than 40% of primary care visits are skin related & skin cancer is the most common cancer that costs over \$10B/year in unnecessary procedures due to lack of training for PCPs
- DermEngine is a cloud-based dermatology platform that offers efficient data acquisition & advanced clinical decision support tools for diagnostics & therapeutics
- Computer Vision & Machine Learning algorithms unlock the power of data to offer more accurate & efficient care while saving costs for payers & providers
- DermEngine’s Artificial Intelligence is vertically implemented across all stakeholders including patients, PCPs, dermatologists, pathologists, oncologists & surgeons & becomes more intelligent by their everyday use
- DermEngine integrates with EMRs, Practice Management Systems & Lab Information Systems to offer clinical intelligence & enhance the workflow efficiency for clinicians

Significant Milestones

DermEngine launched in 2016

DermEngine AI launched in Q1 2017

Established partnerships with clinic chains in 2016

Created the largest database for skin cancer in 2017

Closed over \$1M in sales in 2017

Fundraising

Seeking \$5M Series A





Surrey, United Kingdom



James Roberts
Co-Founder
jroberts@momincubators.com



Matthew Khoory
Co-Founder

Presenting in the
Pulmonology &
Critical Care Showcase

Wednesday
September 27
8:10 am - 9:00 am



Portable, cost-effective incubator for preventing neonatal complications

- Inflatable incubator increases access to care for premature & hypothermic babies worldwide
- Prevents complications associated w/ delayed thermoregulation such as tissue hypoxia, neurologic damage, & transient hyperglycemia which contribute to prolonged stay in the NICU
- Presents a 90% cost savings over conventional incubators & can be compacted to a fraction of the size at less than 10% of the weight
- Naturally insulative which reduces power use between 80-95% lower than that of a conventional incubator
- Innovative design supports easy maintenance & repair

Significant Milestones

Established partnership w/ Morgan Innovation & Technology

MassChallenge UK Diamond Prize Winner (£50K)

Established clinical partnership w/ world renowned NGO

Fundraising

Seeking £5-10M Series A





Boulder, CO



Nick Titus
CEO
nick@myonic.tech



Sam Everett
CFO



Nate Petersen
CTO



Ben Saltz
Chief Design Officer

Presenting in the **Tuesday**
Vascular & **September 26**
Neurovascular Showcase **2:55 pm - 3:45 pm**



Wearable device for allowing paralyzed users to regain control of their muscles


- Through an established partnership with Emotiv, Myonic’s technology utilizes an intuitive Brain Computer Interface (BCI) that allows patients to easily command their muscles
- This technology is non-invasive & safe to use for extended periods of time
- Myonic Move can be fully controlled with nothing more than the user’s thoughts & simple head motions
- A patient can train the device to read their thoughts with the BCI in under 15 minutes
- The device outputs a safe electrical impulse to contract the user’s muscles
- The electrodes are embedded within an easy-to-use sleeve which allows movement of the thumb, four fingers, & elbow to assist in performing basic everyday tasks

Significant Milestones

- Alumni of the Boomtown Accelerator
- Voted the Top Hardware Startup at TechCrunch Disrupt NY 2017
- Completed regulatory assessment
- Launching beta test Q4 2017
- Direct-to-consumer sales Q2 2019

Fundraising

Seeking \$1.5M Seed





Charles Allan
Co-Founder & CEO
charles.allan@nxtsens.com



Ed Harvey, MD
Co-Founder & CMO



George Xereas, PhD
Co-Founder & CTO



Vamsy Chodavarapu, PhD
Co-Founder & VP Research

Pressure monitoring device used to control risks of developing Acute Compartment Syndrome (ACS)

- Competitive Advantages
 - More accurate
 - Continuous monitoring
 - Wireless & cloud based
- Simple Single Use Device
 - No training needed, simple like an IV Class II, 510(k) device
 - Existing reimbursement code
- Economic Value
 - MYOVUE pressure monitoring system allows earlier detection of ACS resulting in:
 - Easier & faster intervention for physicians
 - Saves OR time for hospitals
 - Better outcome for patient
 - Significant economic value for payers

Significant Milestones

Patents filed covering MEMS, device, & insertion method

Pilot animal study completed demonstrating device validity

Started Canadian clinical trial

Clear regulatory pathway

Fundraising

Seeking \$3.5M Seed, of which \$500K remaining





New York, NY



Venk Varadan
Co-Founder & CEO
venk@nanowearinc.com



Vijay Varadan, PhD
Co-Founder & CINO



John Zimmerman, MD
CMO



Prashanth Kumar
CTO

Presenting in the
Cardiovascular
Showcase

Wednesday
September 27
11:40 am - 12:30 pm



Garment with cloth-based nanosensors for remote patient monitoring in CHF disease management

- Patented cloth-based nanosensor technology captures & transmits medical-grade electrophysiological, biochemical, hemodynamic, audio/phonography & actigraphy measurements despite presence of hair, sweat, or other moisture
- SimpleSense is an undergarment used for remote monitoring of CHF by capturing & algorithmically scoring ECG, heart rate variability, respiratory rate, impedance cardiography, thoracic impedance, cardio-phonography & actigraphy
- SimpleSense sends care management teams a daily score alerting physicians & nursing staff of decompensating Heart Failure weeks in advance of a hospitalizing event, enabling teams to intervene during normal office hours
- SimpleSense endpoints are supported by HeartLogic/MultiSENSE trials, which showed 75% success rate in heart failure alerts >14 days in advance of an event when measuring the same metrics

Significant Milestones

Received Class II FDA approval for nanosensors, mobile application & physician portal capturing & transmitting multichannel ECG, HRV & RR
SimpleSense Clinical Data w/ CHF patients

Fundraising

Seeking \$8-9M Series A





Dallas, TX

Closed-loop neurostimulation device for relief of chronic neurological disease



Will Rosellini
Chairman & CEO
will@nexeonmed.com



Brian Blischak
President & CCO



Chris Miller
CFO

- Synapse™ system is a next-generation Deep Brain Stimulation (DBS) technology to treat Parkinson’s Disease
- Precision, closed-loop neuromodulation with recording capabilities helps monitor disease progression & therapy efficacy
- Smart technology eliminates the need for an iterative approach to pulse setting optimization & facilitates expedited, patient-specific programming adaptable to demand over time
- Requires a single surgery to install versus the standard of care, which requires multiple surgeries to update & reprogram

Significant Milestones

Acquired 100 patents from Siemens & Medtronic
Raised \$4.3M private capital & \$9M non-dilutive funding

Fundraising

Received ticker symbol (OTCQB: NXNN) from FINRA & trading



Presenting in the **Tuesday**
Vascular & **September 26**
Neurovascular Showcase **2:55 pm - 3:45 pm**





Montpellier, France



Clémence Franc
Co-Founder & CEO
clemence.franc@nova-gray.com



David Azria, MD, PhD
Co-Founder & CSO



Adeline Torro, PhD
Research Engineer

Biomarker-based test to assess patients' sensitivity for personalizing radiotherapy

- First predictive test of its kind allowing radiation oncologists to tailor treatment to patients
- Identifies, using a single blood sample, patients that will develop severe complications after radiotherapy as well as patients that are eligible for hypofractionated regimen
- Clinically validated by a 10-year prospective multicenter clinical trial w/ 489 breast cancer patients
- Ongoing prospective multicenter trials to validate tests for prostate & lung cancer
- Up to 30% savings on reducing treatment length for low-risk patients & additional savings on avoiding complications

Significant Milestones

CE Marked Q1 2016 (breast cancer test)

First patient out-of-pocket purchase in Q4 2016

Patents filed in 2013 & 2016

Fundraising

Seeking €3M Seed



Presenting in the
In Vitro Diagnostics
Showcase

Tuesday
September 26
9:10 am - 9:50 am





Rahul Puri
Co-Founder & CEO
rahul@oncotab.com



Pinku Mukherjee
Co-Founder & CSO



Taffy Williams
Chairman

Blood test to enable breast cancer detection two years before mammography

- Agkura™ Personal Score (APS) uses a patented monoclonal antibody to detect cancer in patients, especially those with dense breast tissue
- Monitors circulating levels of a tumor specific protein that is present in 95% of breast cancer tissue, across all breast cancer subtypes
- As a supplement to mammography, APS can:
 - Double cancer detection rate
 - Reduce interval cancers by 50%
- May lead to earlier stage diagnosis of breast cancer up to 2 years earlier compared to mammography alone
- Invited by Department of Defense to propose multi-site clinical trial proposal

Significant Milestones


9 US & International patents issued

3 National Cancer Institute Awards (\$830K)

Raised ~\$1.8M to-date from angel investors

Fundraising

Seeking \$15M Series A





Belmont, CA



Justin Barad, MD
Co-Founder & CEO
jhbarad@ossovr.com



Matt Newport
Co-Founder & CTO



Leif Goranson
Director, Marketing



Kathleen Carey
Director, Program Management

Presenting in the
Orthopedic
Showcase

Tuesday
September 26
10:45 am - 11:35 am



Hands-on medical device training platform using virtual reality

- Medical device training platform designed to increase efficiency of surgical training as well as adoption of new medical devices in highly realistic virtual environment
- Current paradigm of cadaver courses are \$300-350K each for a large scale course & are highly inefficient, with 4-6 month gap on average between course & inpatient use
- With Osso VR, physicians can rapidly achieve proficiency with new medical technology & regain the autonomy to decide which devices provide the best value for their patients
- Can also be used for device rep training. High rep turnover & numbers leads to massive onboarding cost (~\$3.4B/yr)
- Osso VR decreases the cost of customer & rep training, while providing a convenient & repeatable option that will increase the ROI on training dollars spent through higher conversion rates & better patient outcomes

Significant Milestones

Working with Top 5 Orthopaedic Device Company

DoE EdSim Challenge Finalist 2017

Completed clinical validation study at UCLA demonstrating 2x improvement in surgical skill

Fundraising

Recently closed \$2M Seed (led by SignalFire)



Houston, TX



Ray Calderon, MD
Founder



Delores Calderon
Co-Founder & COO



Caroline Negley
VP Business Development
cnegley@otricath.com

Presenting in the
Therapeutic Delivery &
Dosing Showcase

Tuesday
September 26
2:10 pm - 2:50 pm

Catheter system for the precision delivery of therapeutic agents to treat solid tumors

- Otricath is a closed loop catheter delivery system
- Enables more control, predictability, & safe therapeutic benefit in application of certain therapies, including chemotherapy & immunotherapies
- Prevents harmful systemic side effects by utilizing a venous-venous delivery technique
- Infuse → Monitor → Withdraw technique
- Transducer with pressure monitoring capability
- Predictable, reliable, & repeatable delivery supported by in-vivo porcine studies
- Real-time analysis during procedure
- Right dose, right place, right time

Significant Milestones

In vivo preclinical studies

Alpha prototype


\$35K 2nd Place Winner at Texas A&M New Ventures Competition 2017

NSF regional I-Corps program 2017

TMCx Medical Device Accelerator 2016

Fundraising

Seeking \$1.5M Seed, of which \$750K remaining





Mountain View, CA



Justin Huelman
Co-Founder & CEO
justin.huelman@gmail.com



Véronique Peiffer, PhD
Co-Founder

Convenient at-home treatment for excessive sweating of the hands (palmar hyperhidrosis)

- ‘Electrical antiperspirant’ in a glove to treat excessive sweating of the hands
- Wear for 30 minutes once weekly to keep hands dry
- Current standards of care (e.g., antiperspirants, systemic drugs, botox injections) are ineffective, invasive, or expensive
- Clinically tested in 9 patients, documenting a very significant reduction in sweat levels (65% on average), with reported meaningful improvement in daily quality of life

Significant Milestones

Completed successful clinical study at Stanford University

Validated patient willingness-to-pay

Portfolio company of the Fogarty Institute for Innovation & StartX

Fundraising

Seeking \$1.5M Seed

Sweat staining before/after
(demonstration on portion of hand only)



Control



Treated (day 7)

Presenting in the
Consumer Health
Showcase

Wednesday
September 27
9:05 am - 9:45 am





Atlanta, GA

Blockchain-secured solution for connecting patients to their health information

- Decentralized population health management tool & patient portal secured by blockchain
- Assists healthcare organizations in improving outcomes via automated chronic care plans
- Streamlines coordination of care by centralizing complete patient history
- Eliminates risk of healthcare breaches through decentralized blockchain technology
- Patient engagement software capability

Significant Milestones

Two provisional patents filed
 2000+ customer validation interviews completed with the aid of Colorado Permanente Medical Group

Funding


Raised \$7.2M in Q2 2017 Token Sale



Chrissa McFarlane
 Founder & CEO
chrissa@patientory.com



Rob Campbell
 Chief Solutions Architect



Presenting in the
 Consumer Health
 Showcase

Wednesday
 September 27
 9:05 am - 9:45 am





Bethesda, MA



Charles Berul, MD
CEO



Axel Krieger, PhD
CTO



Bradley Clark, MD
CMO



Justin Opfermann, MS
Lead Engineer
jopferma@cnmc.org

Presenting in the
Vascular &
Neurovascular Showcase

Tuesday
September 26
2:55 pm - 3:45 pm



Access tool for percutaneous epicardial procedures to replace open-chest surgery

- PeriPath is designed specifically for the pediatric population & converts open chest surgery to a single, percutaneous incision procedure
- First multi-lumen tool for access of the pericardial space
- Provides direct visualization through a deflectable endoscope
- Eliminates the need for procedural fluoroscopy
- Accommodates 4mm endoscopes & any cardiac therapy up to 8mm
- Compatible with all commercial delivery tools for epicardial ablation, pacing, & defibrillation therapy
- Reduces collateral tissue damage, post surgery pain, & recovery time

Significant Milestones

Animal study in 15 infant piglets completed
 National Capital Consortium: Pediatric Device Innovation 2016 Top 3 (\$50K)
 Clinical Translational Science Institute - Pediatric Innovation Fund Award Winner 2016 (\$50K)
 Completed pre-submission meeting with FDA & established 510(k) approval pathway
 Received \$175K philanthropic donation

Fundraising

Seeking \$8-10M Series A

PeriPath – A Single Site Access Tool



PharmaJet

Golden, CO



Ron Lowy
CEO



Jeffrey Jordan
CFO



Heather Potters
Chief BD Officer
heather.potters@pharmajet.com



Chris Cappello
COO

Presenting in the
Therapeutic Delivery &
Dosing Showcase

Tuesday
September 26
2:10 pm - 2:50 pm



Safe, fast, & easy needle-free vaccine/biologic delivery system

- Needle-free vaccine delivery for intramuscular, subcutaneous, or intradermal use
- Lack of needle eliminates needle stick injuries & disease transmission
- Improves immune response of some vaccines & therapeutics
- Savings generated for each injection through dose sparing, dose efficiency, & elimination of sharps risk & disposal
- Completed largest needle-free vaccination study for influenza resulting in first ever FDA issued vaccine label change for PharmaJet as a method of administration (Stratis®)
- Pre-fillable syringe in development
- Fractional dose polio clinical confirmation by World Health Organization (WHO) demonstrating 60% less vaccine is superior in immune response (2 fractional doses fIPV/ID with PharmaJet Tropis® vs. 1 full dose IPV with needle/syringe)

Significant Milestones

Several regulatory device & on label approvals for Stratis (IM/SC) device, including FDA, CE Mark, DCGI, WHO PQS & others

Stratis commercially launched Q4 2015 in US; Q1 2017 in India

Tropis intradermal device has CE Mark & is completing WHO PQS

Fundraising

Seeking \$10M Series G



Durham, NC



Ken Bernstein
Co-Founder & CEO
ken.bernstein@pneumonics.com



Ric Telford
Co-Founder & COO



Bryce Hill, PhD
Co-Founder & CTO



Bret Askeland
Lead Software Developer

Presenting in the
Pulmonology &
Critical Care Showcase

Wednesday
September 27
8:10 am - 9:00 am

Respiratory monitoring for the detection of opioid-induced respiratory depression

- PneuMotion combines respiratory rate & oxygen saturation into a single critical parameter, ensuring timely intervention & reduction of false alarms
- Respiratory acoustics & chest wall motion analysis provides sensitive & reliable airway obstruction detection
- Proprietary algorithm for the detection of obstructive sleep apnea
- Bluetooth & Wi-Fi capability for both bedside & remote patient monitoring
- Seamless integration with hospital's EHR & telecom network

Significant Milestones

Proof of concept completed
Design validation in progress
Clinical validation in contract
FDA 510(k) Submission
Soft launch Q4 2018
Product launch Q2 2019

Fundraising

Seeking \$750K Seed





Rockville, MD

Cost effective, office-based MRI with cellular spatial resolution



Amit Vohra, PhD, MBA
President & CEO
avohra@promaxo.com



Michael Bartholomew
CCO



Irving Weinberg, MD, PhD
Acting CMO



Aleksander Nacev, PhD
Technology Lead

- Compact, single sided MRI with high spatial resolution comparable to histology
- Focused on pelvic region & prostate disease management
- Product pipeline encompasses office MRI, biopsy & ablation tools, & CAD software
- Non-invasive with no unpleasant side effects to patients
- Enables a point-of-care shift, real-time targeted biopsy & focal treatment
- Established reimbursements & attractive return on purchase for practices & hospitals
- Demonstrated safety in a double-blinded prospective trial on 26 adult subjects
- Seasoned management supported by premier clinicians - Vipul Patel, Ash Tewari, Neal Shore, & business experts - Dushyant Chipalkatty, Diego Olego, Martin Bradshaw

Significant Milestones

Exclusive worldwide license to 8 issued & 25 pending patents

Raised \$11.6M (\$9M NIH & NSF/\$1.6M bridge round/\$1M Series A) to date

Fundraising

\$4.5M Series A



Presenting in the **Wednesday**
Advanced Imaging **September 27**
Diagnostics Showcase **10:45 am - 11:35 am**





Madison, WI



Luke Bonney
Co-Founder & CEO



Niko Skievaski
Co-Founder & President
niko@redoxengine.com



James Lloyd
Co-Founder & CTO

EHR integration, simplified. Redox is the modern integration engine for healthcare


- Through a single connection, users can authorize the exchange of healthcare data with any partner
- Redox maintains connectivity & data standardization across the largest network of health systems, EHRs, & enterprise healthcare applications
- Users see integration projects accelerate to days instead of months/years
- Software developers experience a modern developer environment & standard healthcare-specific APIs
- Redox’s customers include by health systems, software vendors, EHRs, & payors who use the engine to scale interoperability

Significant Milestones

Connected to 120 health systems, 30 EHRs, & 500+ digital health applications
45 employees, HITRUST Certified
Raised \$14M in total funding

Funding

Closed \$9M Series B in Q1 2017



Presenting in the **Tuesday**
Health Care IT & **September 26**
Digital Health Showcase **9:55 am - 10:35 am**





Tucson, AZ



Dave Kane
President & CEO
dave.kane@rmdevices.com



Mike Pedro, MD
CMO & CTO



Tom Reilly
COO

Presenting in the
Pulmonology &
Critical Care Showcase

Wednesday
September 27
8:10 am - 9:00 am



Non-invasive nasal ventilation platform for treating sedation-related respiratory compromise

- SuperNO₂VA™ nasal platform may be used pre-op, intra-op & post-op for general anesthesia & deep sedation (GADS) cases
- Continuous nasal ventilation system is the only nasal mask on the market that relieves upper airway obstruction
- Ability to measure EtCO₂ aligns with CMS standards of post-operative care guidelines
- Clinical trial demonstrated improved oxygenation & ventilation compared to the current standard of care
- Single-use device, applicable to 60 million procedures in the US
- >8,000 patients have undergone Nasal Oxygenation & Ventilation of the Airway (NOVA) therapy

Significant Milestones

SuperNO₂VA™ mask commercial launch (2016)
Patents issued (utility & design)

Fundraising

Seeking \$10M Series B



Denver, CO



Rob Valuck, PhD
Co-Founder & CSO



Chris Ennis
Co-Founder & CTO
chris@rxassurance.com



Rick May, MD
CMO

Presenting in the **Tuesday**
Health Care IT & **September 26**
Digital Health Showcase **9:55 am - 10:35 am**

Intelligent solutions for reducing risk & increasing compliance for opioid prescribers & their patients

- OpiSafe provides medical professionals access to all relevant opiate-prescribing patient data (ePROs, PDMP, EHR, & lab results) in one place
- Streamlines tracking opioid use & assists w/ following CDC guidelines
- Improves workflow efficiency & improves outcomes by automating the delivery of clinical assessments
- OpiSafe promotes patient engagement & helps care providers lower liability risks, thus save on medical malpractice
- 450+ practices across the US use OpiSafe resulting in 5K+ lab reports generated & 20K+ PDMP checks per month

Significant Milestones

Signed contracts w/ 12 pain & MAT clinics
Received CO OEDIT Advanced Industries Grant (\$250K)

Fundraising

Seeking \$750K Seed



 **OpiSafe**

Reducing the Time Burden of Managing Patients

 +  + 

Automated PDMP Checks + Summarized Urinalysis + Interactive Assessment Management

OpiSafe reduces clinical time from 5+ minutes to 60 seconds or less



Dublin, Ireland



Colm McGarvey
CEO
megarvco@tcd.ie



Garrett Ryan, PhD
CTO

Presenting in the
Pulmonology &
Critical Care Showcase

Wednesday
September 27
8:10 am - 9:00 am



Smart access needle preventing lung collapse & hospital admissions post lung biopsy

- Simple, effective & patent protected technology to prevent pneumothorax, a collapsed lung: the leading hospital cost & complication post lung biopsy
- 1 in 3 patients undergoing a lung biopsy suffer from a pneumothorax & many patients require hospitalization for invasive treatment at average cost of \$11K per patient
- Sterile, single-use ‘smart’ access needle allows clinicians to seal the biopsy route pre-biopsy; Biopsy carried out through this air tight seal, prevents pneumothorax during or after the procedure
- Patient safely returns home on same day as biopsy with no risk of pneumothorax & no costly hospital admission
- Large growth market: 1.1M lung biopsy procedures globally pa.
- Therapeutic opportunity for prevention of pneumothorax during percutaneous lung ablation

Significant Milestones

Developed prototype

Strong proof of concept data from *in vivo* studies in porcine model


International clinical validation

Experienced founding team with world class advisors

Fundraising

Seeking €3.5M Seed

In Vivo results in porcine model



1. CT scan before procedure.

2. CT scan after successful delivery of sealant & contrast into pleural cavity with Selio device.



Redwood City, CA

Platform to improve diagnosis & treatment of brain disorders including autism & ADHD



Malekeh Amini
Founder & CEO
malekeh@trayt.io



Carl Feinstein, MD
Co-Founder & CMO



Eric Saltzman
Co-Founder & COO



Hitesh Kalra
Co-Founder, CTO

- Data collection & analytic platform to improve diagnosis of & treatment outcomes in neurodevelopmental & brain disorders
- Provides real-time access to the patient's overall health profile & daily progress across set goals, reducing intervention cycles
- Connects parents, physicians, & therapists through comprehensive reporting, optimizing engagement for daily behavioral health management
- Customizable clinical dashboard, utilizing artificial intelligence for both patient-directed & disease aggregate decision-making

Significant Milestones

Patent filed

Alpha & beta apps released; beta enrollment in progress

Established partnership with the Mind Institute at UC Davis

Raised \$1.6M to date in funding

Fundraising

Seeking \$4-5M Series A



Presenting in the
Consumer Health
Showcase

Wednesday
September 27
9:05 am - 9:45 am





Crosby, MS

Spinal decompression device for relieving back pain



Paul Leake
Co-Founder & CEO
paul.leake@vertecore.com



Paul Montalvo
Co-Founder &
Chief Design Officer

- VerteCore Lift decompresses the spine utilizing an easy-to-use dual support harness & ratcheting system
- Lightweight device is comfortable & slim enough to be worn under normal clothing allowing patients to continue w/ normal daily routines while receiving spinal decompression therapy
- Mobile product to address evidence-based treatment for spinal decompression, potentially eliminating the need for long-term opioid use
- Reduces lost worker productivity & minimizes risk of repeated injury due to insufficient recovery

Significant Milestones

Received FDA approval in Q2 2016

Indiegogo Campaign resulted in \$408K in pre-sales

Fundraising

Seeking \$1 M Seed



Presenting in the
Orthopedic
Showcase

Tuesday
September 26
10:45 am - 11:35 am





College Station, TX



Alan Glowczwski, MD
Founder & CEO



April Lovelady, PhD
CTO
april.lovelady
@voyagerbiomedical.com

Presenting in the **Tuesday**
Vascular & **September 26**
Neurovascular Showcase **2:55 pm - 3:45 pm**



Implantable device to improve vascular access for dialysis patients


- Ark is designed to eliminate problems associated with venous access
- Facilitates fistula usage, the preferred method of access incentivized by Medicare
- Acts as a supportive exoskeleton, strengthening the vessel, improving the capability of enduring repeated needle punctures
- Enables earlier vascular access by promoting fistula maturity & restores failed fistulas
- Provides value to hospitals & surgical centers by decreasing inpatient hospitalizations, decreasing the number of hospital days & improving patient outcomes

Significant Milestones

Provisional patent filed
Raised \$225K to date from founders

Fundraising

Seeking \$750K Seed





Oklahoma, OK



James Long, MD, PhD
President & CMO



Richard Wampler, MD
Lead Designer



Kurt Dasse, PhD
Executive Director



Trevor Snyder, PhD
VP R&D
trevor.snyder@vadovations.com



Ryan Stanfield, PhD
VP Engineering

Presenting in the
Cardiovascular
Showcase

Wednesday
September 27
11:40 am - 12:30 pm



Smaller, safer blood pump to help infants & children with heart failure

- Angel Assist is a miniature VAD platform designed specifically for the pediatric population (down to 3kg)
- Greatest need is for the smallest children
- Current treatment options include 30+ year technology obsolete in adults, off label use of adult devices in larger kids, or doing nothing
- The ‘AA’ battery-sized implantable pump was designed to:
 - ♥ Reduce complications
 - ♥ Enable hospital discharge
 - ♥ Substantially reduce the total cost of care
- Overall, VADovations seeks to capture underserved niche markets to confirm technology performance, generate revenues, cultivate clinical champions, & then pursue the larger adult heart failure market

Significant Milestones

U.S. Humanitarian Use Designation pending
Raised \$30M to date (\$5M Series A/\$15M convertible debt, \$10M grants)

Fundraising

Seeking \$10M to commence 1st in Human implants



Mountain View, CA



Gabriel Sanchez, PhD
CEO
gabriel@zebramedtech.com



Scott Delp, PhD
Co-Founder



Mark Schnitzer, PhD
Co-Founder

Presenting in the
Dermatology & Wound
Healing Showcase

Tuesday
September 26
11:40 am - 12:20 pm

Live cellular imaging using a handheld device for real-time cancer detection

- EagleCyte uses dynamic nonlinear microscopy for non-invasive skin pathology
- Other companies simplify skin cancer screening; we allow physicians to diagnose immediately
- Delivers H&E-quality contrast without dyes
- Multiple medical applications for women's health, neuromuscular, GI oncology, & dermatology

Significant Milestones

Clinical prototype developed
Completed feasibility study

Fundraising

Seeking \$8M Series A



Be sure to visit the Innovation Pavilion during these times for demonstrations from the companies listed below:



DAY



START



END

Tuesday

10:15 am

11:15 am

3:30 pm

4:00 pm

Wednesday

8:00 am


9:00 am

10:15 am

11:15 am


**Join us on Tuesday afternoon from 4:00 pm – 5:30 pm
in the Convention Center – Grand Ballroom for the
MedTech Innovator \$500K Competition Finals**




 @MedTechAwards
#MedTechInnovator



Powered by  AdvaMed

 @MedTechCon
#MedTechCon

 The MedTech
Conference